Henry O. Gosebruch - Mar 1, 2022 Form 4/A - Amendment Insider Report for AbbVie Inc. (ABBV)

Role: EVP, Chief Strategy Officer
Signature: Steven L. Scrogham, attorney-in-fact for Henry O. Gosebruch
Stock symbol: ABBV
Transactions as of: Mar 1, 2022
Transactions value $: -$3,682,189
Form type: 4/A - Amendment
Date filed: 5/20/2022, 05:00 PM
Date Of Original Report: Mar 2, 2022
Previous filing: Mar 1, 2022
Next filing: May 20, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABBV	Common Stock, $0.01 par value	Sale	-$2.31M	-15.7K	-20.04%	$146.81	62.8K	Mar 1, 2022	In trust	F1
transaction	ABBV	Common Stock, $0.01 par value	Sale	-$763K	-5.17K	-8.23%	$147.60	57.6K	Mar 1, 2022	In trust	F2
transaction	ABBV	Common Stock, $0.01 par value	Sale	-$595K	-4K	-6.94%	$148.71	53.6K	Mar 1, 2022	In trust	F3
transaction	ABBV	Common Stock, $0.01 par value	Sale	-$14.9K	-100	-0.19%	$149.38	53.5K	Mar 1, 2022	In trust	F4, F5, F7
holding	ABBV	Common Stock, $0.01 par value						41.6K	Mar 1, 2022	Direct	F7
holding	ABBV	Common Stock, $0.01 par value						3.46K	Mar 1, 2022	Profit sharing trust	F6

Showing 1 to 6 of 6 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.31 to $147.30 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.35 to $148.11 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.37 to $148.96 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.38 to $149.39 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5	The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust.
F6	Balance in AbbVie Savings program as of January 31, 2022.
F7	Due to an administrative error, the original Form 4 filed on March 2, 2022 incorrectly reported that the 25,000 securities sold on March 1, 2022 were securities directly owned by the reporting person. Instead, the securities sold on that date were securities indirectly owned in trust by the reporting person. This amended Form 4 corrects that error.

Remarks:

The sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).